Greenwich Lifesciences Inc

Chart & Performance

D1W1MN

P/E

—

P/S

—

EPS

—

Div Yield, %

0.00%

Shrs. gr., 5y

1.43%

Rev. gr., 5y

Revenues

Net income

-9m

L+16.84%

CFO

-6m

L+4.49%

Earnings

May 19, 2025

Profile

Greenwich LifeSciences, Inc., a clinical stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is the GP2, an immunotherapy, which has completed Phase IIb clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas.

URL

https://greenwichlifesciences.com/

IPO date

Sep 25, 2020

Employees

Domiciled in

Incorporated in

Valuation

Order:

Title USD in thousands, except ratios and share amounts	FY	FY	FY	FY	FY	FY	FY
Title USD in thousands, except ratios and share amounts	2023‑12	2022‑12	2021‑12	2020‑12	2019‑12	2018‑12	2017‑12
Income
Revenues
Cost of revenue	9,331	8,044
Unusual Expense (Income)
NOPBT	(9,331)	(8,044)
NOPBT Margin
Operating Taxes		(215)
Tax Rate
NOPAT	(9,331)	(7,829)
Net income	(8,892) 16.84%	(7,610) 67.51%
Dividends
Dividend yield
Proceeds from repurchase of equity		(7,536)
BB yield		3.84%
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt	(6,989)	(13,468)
Cash flow
Cash from operating activities	(6,479)	(6,200)
CAPEX
Cash from investing activities
Cash from financing activities		(7,536)
FCF	(9,331)	(7,829)
Balance
Cash	6,989	13,468
Long term investments
Excess cash	6,989	13,468
Stockholders' equity	(50,352)	(41,460)
Invested Capital	57,052	54,674
ROIC
ROCE
EV
Common stock shares outstanding	12,848	12,914
Price	10.52 -30.79%	15.20 -37.53%
Market cap	135,163 -31.14%	196,290 -37.67%
EV	128,173	182,822
EBITDA	(9,328)	(8,040)
EV/EBITDA
Interest		215
Interest/NOPBT